NVS Novartis AG
Healthcare$150.80-0.80%ClosedMarket Cap: $287.74B
As of 2026-05-26
Valuation
P/E (TTM)
21.32
PEG
1.25
P/B
7.54
P/S
5.25
EV/EBITDA
15.16
DCF Value
$273.77
FCF Yield
5.7%
Div Yield
3.1%
Margins & Returns
Gross Margin
75.1%
Operating Margin
29.9%
Net Margin
24.3%
ROE
31.5%
ROA
11.3%
ROIC
14.9%
Income Statement
Periods shown are fiscal year quarters (may differ from calendar year)
| Period | Revenue | Gross Margin | Operating Income | Net Income | EPS | Dividend |
|---|---|---|---|---|---|---|
| Q1 null | $13.52B | 74.4% | $4.24B | $3.16B | $— | $3.08 |
| Q4 null | $13.33B | 73.4% | $3.52B | $2.41B | $— | — |
| FY null | $54.81B | 75.0% | $17.07B | $14.06B | $— | $3.28 |
| Q3 null | $14.36B | 75.4% | $4.50B | $3.93B | $— | — |
| Q2 null | $14.84B | 77.6% | $4.86B | $4.04B | $— | — |
| Q1 null | $13.62B | 76.3% | $4.66B | $3.61B | $— | $3.28 |
| Q4 null | $13.56B | 75.5% | $3.53B | $2.82B | $— | — |
| FY null | $51.72B | 75.2% | $14.54B | $11.94B | $— | $3.20 |
| Q3 null | $13.17B | 75.4% | $3.63B | $3.19B | $— | — |
| Q2 null | $12.87B | 75.3% | $4.01B | $3.25B | $— | — |
| Q1 null | $12.12B | 74.5% | $3.37B | $2.69B | $— | $3.20 |
| Q4 2023 | $11.78B | 74.3% | $2.58B | $8.48B | $4.11 | — |